EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead

Carlos Jose Pirola

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Carlos Jose Pirola. Beteiligte Einrichtung: National Scientific and Technical Research Council and Translational Research in Health Center, Systems Biology of Complex Diseases Department, Maimo…. Hauptthemen laut MEDLINE: Drug Repositioning, Imidazoles, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The article discusses the potential of repurposing daclatasvir, an FDA-approved anti-HCV drug, for treating metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH). The study by Shu et al. identifies daclatasvir as a potent inhibitor of perilipin-2 (PLIN2), a protein central to lipid droplet stability and metabolic homeostasis. Daclatasvir enhances MARCH6-mediated ubiquitination of PLIN2, leading to its degradation, which reduces lipid accumulation, inflammation, and fibrosis-key features of MASLD and MASH. Preclinical models demonstrate its ability to improve lipid metabolism, reduce inflammation, and alleviate liver fibrosis. Despite promising findings, challenges remain. Clinical trials are needed to validate its efficacy and safety in humans, as animal models cannot fully replicate the multifactorial nature of MASLD. Long-term safety and potential off-target effects also require evaluation, especially since PLIN2 may protect against other liver conditions. The study highlights the need for broader screening of FDA-approved drugs and exploration of alternative pathways for PLIN2 regulation. While daclatasvir shows promise, further research is essential to address these gaps and advance its clinical application for MASLD therapy. The findings underscore the potential of drug repurposing as a cost-effective strategy for unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningImidazolesFatty LiverHumansCarbamatesPyrrolidinesValineAnimals

Stichwörter der Autor:innen

MASHPLIN2antiviral drugslipophagyproteasome

Substanzen

CarbamatesPyrrolidinesImidazolesValinedaclatasvir

Autor:innen und Institutionen

  • National Scientific and Technical Research Council and Translational Research in Health Center, Systems Biology of Complex Diseases Department, Maimonides University, Buenos Aires, Argentina. Electronic address: pirola.…

Zitieren

APA

Pirola, C. J. (2025). Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100857

Vancouver

Pirola CJ. Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100857

BibTeX
@article{Pirola2025,
  author = {Pirola, Carlos Jose},
  title = {Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100857}
}
Kostenlos starten →